US Patent Issued to Hoffmann-La Roche on July 29 for "Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent" (Canadian Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,371,748, issued on July 29, was assigned to Hoffmann-La Roche Inc. (Little Falls, N.J.).

"Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent" was invented by Marie-Pierre Dube (Montreal) and Jean-Claude Tardif (Montreal).

According to the abstract* released by the U.S. Patent & Trademark Office: "Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator."

The patent was filed on June 16, 2022, under Application No. 17/842,282.

*For further information, including images, charts and tables, pl...